As previously reported, last month the UK's Office of Fair Trading announced that following its review of the practice of Retail Price Maintenance on over-the-counter medicines, it has decided to apply to the Court to hold a new hearing on the subject (Marketletters passim).
According to the Proprietary Association of Great Britain, the trade body representing OTC drugmakers, the impression given in this announcement is that a decision has been made that RPM will end.
This is far from the case, it stresses, adding that it is important to understand the legal position and the facts surrounding this issue, which are that:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze